LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: rVWF: treatment finally reaches the modern age.

    Metjian, Ara D

    Blood

    2015  Volume 126, Issue 17, Page(s) 1975–1976

    Abstract: In this issue of Blood, Gill et al describe the results of the first phase 3 clinical trial evaluating recombinant von Willebrand factor (rVWF) for the treatment of hemorrhagic events in all patients with von Willebrand disease (VWD). ...

    Abstract In this issue of Blood, Gill et al describe the results of the first phase 3 clinical trial evaluating recombinant von Willebrand factor (rVWF) for the treatment of hemorrhagic events in all patients with von Willebrand disease (VWD).
    MeSH term(s) Female ; Hemostatics ; Humans ; Male ; Recombinant Proteins/pharmacokinetics ; von Willebrand Diseases/drug therapy ; von Willebrand Factor/pharmacokinetics
    Chemical Substances Hemostatics ; Recombinant Proteins ; von Willebrand Factor
    Language English
    Publishing date 2015-10-22
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood-2015-08-664052
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.140: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 364: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Acquired, non-amyloid related factor X deficiency: review of the literature.

    Lee, G / Duan-Porter, W / Metjian, Ara D

    Haemophilia : the official journal of the World Federation of Hemophilia

    2013  Volume 18, Issue 5, Page(s) 655–663

    MeSH term(s) Aged ; Amyloidosis/complications ; Blood Coagulation Factor Inhibitors/blood ; Factor X/antagonists & inhibitors ; Factor X/immunology ; Factor X Deficiency/blood ; Factor X Deficiency/etiology ; Factor X Deficiency/immunology ; Factor X Deficiency/therapy ; Humans ; Male ; Prognosis ; Respiratory Tract Infections/complications ; Treatment Outcome
    Chemical Substances Blood Coagulation Factor Inhibitors ; Factor X (9001-29-0)
    Language English
    Publishing date 2013-02-20
    Publishing country England
    Document type Case Reports ; Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 1229713-6
    ISSN 1365-2516 ; 1351-8216 ; 1355-0691
    ISSN (online) 1365-2516
    ISSN 1351-8216 ; 1355-0691
    DOI 10.1111/j.1365-2516.2012.02773.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4249: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 450: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Use of a thrombopoietin mimetic for chronic immune thrombocytopenic purpura in pregnancy.

    Patil, Avinash S / Dotters-Katz, Sarah K / Metjian, Ara D / James, Andra H / Swamy, Geeta K

    Obstetrics and gynecology

    2013  Volume 122, Issue 2 Pt 2, Page(s) 483–485

    Abstract: Background: Romiplostim, a thrombopoietin mimetic, is a novel therapeutic option for patients with chronic immune thrombocytopenic purpura. We report on the effects of romiplostim use throughout pregnancy.: Case: A 28-year-old primigravid woman with ... ...

    Abstract Background: Romiplostim, a thrombopoietin mimetic, is a novel therapeutic option for patients with chronic immune thrombocytopenic purpura. We report on the effects of romiplostim use throughout pregnancy.
    Case: A 28-year-old primigravid woman with chronic immune thrombocytopenic purpura initiated a planned pregnancy on romiplostim. The second and third trimesters were marked by a cyclic pattern of thrombocytopenia requiring supplemental corticosteroids or intravenous immunoglobulin and resultant thrombocytosis. Increased romiplostim doses and daily corticosteroids stabilized the platelet count before induction of labor at 33 weeks of gestation. The newborn manifested intraventricular hemorrhage at birth, although no developmental delay was present on follow-up at 10 months of age.
    Conclusion: The decreased efficacy of romiplostim monotherapy is attributed to increased target-mediated drug disposition and the physiologic changes of pregnancy. Safety concerns still exist for the developmental effects of romiplostim on the fetus.
    MeSH term(s) Adult ; Female ; Humans ; Pregnancy ; Pregnancy Complications, Hematologic/drug therapy ; Purpura, Thrombocytopenic, Idiopathic/drug therapy ; Receptors, Fc/therapeutic use ; Receptors, Thrombopoietin/agonists ; Recombinant Fusion Proteins/therapeutic use ; Thrombopoietin/therapeutic use
    Chemical Substances Receptors, Fc ; Receptors, Thrombopoietin ; Recombinant Fusion Proteins ; Thrombopoietin (9014-42-0) ; romiplostim (GN5XU2DXKV)
    Language English
    Publishing date 2013-06-27
    Publishing country United States
    Document type Case Reports ; Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 207330-4
    ISSN 1873-233X ; 0029-7844
    ISSN (online) 1873-233X
    ISSN 0029-7844
    DOI 10.1097/AOG.0b013e31828d5b56
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Um I Zs.230: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Indications for and outcomes of therapeutic plasma exchange after cardiac transplantation: A single center retrospective study.

    Onwuemene, Oluwatoyosi A / Grambow, Steven C / Patel, Chetan B / Mentz, Robert J / Milano, Carmelo A / Rogers, Joseph G / Metjian, Ara D / Arepally, Gowthami M / Ortel, Thomas L

    Journal of clinical apheresis

    2018  Volume 33, Issue 4, Page(s) 469–479

    Abstract: Introduction: Limited data are available describing indications for and outcomes of therapeutic plasma exchange (TPE) in cardiac transplantation.: Methods: In a retrospective study of patients who underwent cardiac transplantation at Duke University ... ...

    Abstract Introduction: Limited data are available describing indications for and outcomes of therapeutic plasma exchange (TPE) in cardiac transplantation.
    Methods: In a retrospective study of patients who underwent cardiac transplantation at Duke University Medical Center from 2010 to 2014, we reviewed 3 TPE treatment patterns: a Single TPE procedure within 24 h of transplant; Multiple TPE procedures initiated within 24 h of transplant; and 1 or more TPE procedures beginning >24 h post-transplant. Primary and secondary outcomes were overall survival (OS) and TPE survival (TS), respectively.
    Results: Of 313 patients meeting study criteria, 109 (35%) underwent TPE. TPE was initiated in 82 patients within 24 h, 40 (37%) receiving a single procedure (Single TPE), and 42 (38%) multiple procedures (Multiple TPE). Twenty-seven (25%) began TPE >24 h after transplant (Delayed TPE). The most common TPE indication was elevated/positive panel reactive or human leukocyte antigen antibodies (32%). With a median follow-up of 49 months, the non-TPE treated and Single TPE cohorts had similar OS (HR 1.08 [CI, 0.54, 2.14], P = .84), while the Multiple and Delayed TPE cohorts had worse OS (HR 2.62 [CI, 1.53, 4.49] and HR 1.98 [CI, 1.02, 3.83], respectively). The Multiple and Delayed TPE cohorts also had worse TS (HR 2.59 [CI, 1.31, 5.14] and HR 3.18 [CI, 1.56, 6.50], respectively). Infection rates did not differ between groups but was independently associated with OS (HR 2.31 [CI, 1.50, 3.54]).
    Conclusions: TPE is an important therapeutic modality in cardiac transplant patients. Prospective studies are needed to better define TPE's different roles in this patient population.
    MeSH term(s) Adult ; Aged ; Antibodies/blood ; Female ; Follow-Up Studies ; HLA Antigens/immunology ; Heart Transplantation/methods ; Heart Transplantation/mortality ; Humans ; Male ; Middle Aged ; Plasma Exchange/methods ; Plasma Exchange/mortality ; Retrospective Studies ; Survival Analysis
    Chemical Substances Antibodies ; HLA Antigens
    Language English
    Publishing date 2018-03-10
    Publishing country United States
    Document type Journal Article
    ZDB-ID 604912-6
    ISSN 1098-1101 ; 0733-2459
    ISSN (online) 1098-1101
    ISSN 0733-2459
    DOI 10.1002/jca.21622
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1831: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia.

    Whitlatch, Nicole L / Kong, David F / Metjian, Ara D / Arepally, Gowthami M / Ortel, Thomas L

    Blood

    2010  Volume 116, Issue 10, Page(s) 1761–1766

    Abstract: The diagnosis of heparin-induced thrombocytopenia (HIT) requires detection of antibodies to the heparin/platelet factor 4 (PF4) complexes via enzyme-linked immunosorbent assay. Addition of excess heparin to the sample decreases the optical density by 50% ...

    Abstract The diagnosis of heparin-induced thrombocytopenia (HIT) requires detection of antibodies to the heparin/platelet factor 4 (PF4) complexes via enzyme-linked immunosorbent assay. Addition of excess heparin to the sample decreases the optical density by 50% or more and confirms the presence of these antibodies. One hundred fifteen patients with anti-heparin/PF4 antibodies detected by enzyme-linked immunosorbent assay were classified as clinically HIT-positive or HIT-negative, followed by confirmation with excess heparin. A multivariate logistic regression model was fitted to estimate relationships between patient characteristics, laboratory findings, and clinical HIT status. This model was validated on an independent sample of 97 patients with anti-heparin/PF4 antibodies. No relationship between age, race, or sex and clinical HIT status was found. Maximal optical density and confirmatory positive status independently predicted HIT in multivariate analysis. Predictive accuracy on the training set (c-index 0.78, Brier score 0.17) was maintained when the algorithm was applied to the independent validation population (c-index 0.80, Brier score 0.20). This study quantifies the clinical utility of the confirmatory test to diagnose HIT. On the basis of data from the heparin/PF4 enzyme-linked immunosorbent assay and confirmatory assays, a predictive computer algorithm could distinguish patients likely to have HIT from those who do not.
    MeSH term(s) Antibodies/analysis ; Antibodies/immunology ; Anticoagulants/adverse effects ; Anticoagulants/immunology ; Dose-Response Relationship, Drug ; Enzyme-Linked Immunosorbent Assay/methods ; Female ; Heparin/adverse effects ; Heparin/immunology ; Humans ; Logistic Models ; Male ; Middle Aged ; Multivariate Analysis ; Platelet Factor 4/immunology ; Reproducibility of Results ; Retrospective Studies ; Thrombocytopenia/chemically induced ; Thrombocytopenia/diagnosis ; Thrombocytopenia/immunology
    Chemical Substances Antibodies ; Anticoagulants ; Platelet Factor 4 (37270-94-3) ; Heparin (9005-49-6)
    Language English
    Publishing date 2010-05-27
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, P.H.S. ; Validation Study
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood-2010-01-262659
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.140: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 364: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top